Cogent Biosciences, Inc.
COGT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $98 | $53 | $140 | $220 |
| Short-Term Investments | $189 | $212 | $119 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $9 | $5 | $6 | $3 |
| Total Curr. Assets | $296 | $271 | $265 | $223 |
| Property Plant & Equip (Net) | $27 | $30 | $31 | $4 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $7 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $5 | $5 | $5 | $5 |
| Total NC Assets | $31 | $43 | $36 | $9 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $328 | $313 | $301 | $232 |
| Liabilities | – | – | – | – |
| Payables | $12 | $11 | $6 | $3 |
| Short-Term Debt | $2 | $1 | $1 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $2 | $3 |
| Other Curr. Liab. | $42 | $26 | $18 | $8 |
| Total Curr. Liab. | $56 | $38 | $27 | $17 |
| LT Debt | $16 | $17 | $18 | $1 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $16 | $17 | $18 | $1 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $17 | $19 | $20 | $3 |
| Total Liabilities | $72 | $56 | $45 | $18 |
| Equity | – | – | – | – |
| Pref Stock | $111 | $60 | $66 | $85 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$859 | -$604 | -$411 | -$271 |
| AOCI | $0 | $0 | -$0 | $0 |
| Other Equity | $1,005 | $801 | $601 | $400 |
| Total Equity | $256 | $258 | $256 | $214 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $328 | $313 | $301 | $232 |
| Net Debt | -$81 | -$34 | -$120 | -$217 |